N-acetyl mannosamine as a therapeutic agent
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMarjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
Claims20
A method of increasing sialic acid in a mammal in need thereof comprising administering an effective amount of a sialic acid precursor, N-acetyl mannosamine or a derivative thereof, to the mammal to thereby increase sialic acid in the mammal, wherein the derivative consists of Formula I;
- wherein:
- R1, R3, R4, or R5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl;
- and R2 is lower alkyl, lower alkanoylalkyl, or lower alkyl alkanoyloxy.
A method of treating a kidney disorder in a mammal comprising administering a therapeutic amount of N-acetyl mannosamine to the mammal, wherein the kidney disorder involves proteinuria and hematuria.
(canceled)
(canceled)
A method of increasing sialic acid biosynthesis in a mammal comprising administering to the mammal an effective amount of a N-acetyl mannosamine derivative, wherein the N-acetyl mannosamine derivative consists of Formula I;
- and,
- wherein R1, R3, R4, or R5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl;
- and R2 is lower alkyl, lower alkanoylalkyl, or lower alkyl alkanoyloxy.
Dependencies are inferred from the claim text.